Trial Profile
A first in man trial to determine the pharmacokinetics, safety, tolerability, and to monitor hormonal changes after single and multiple subcutaneous BIM23B065 administrations
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs BIM 23B065 (Primary)
- Indications Acromegaly
- Focus Adverse reactions; First in man; Pharmacokinetics
- 18 Nov 2018 New trial record
- 26 Oct 2018 Results published in the Journal of Clinical Endocrinology and Metabolism